Evidence map›Paper›PMID 32720098›Full record

ArticleJournal of biomolecular NMR2020

The role of NMR in leveraging dynamics and entropy in drug design.

Abhinav Dubey, Koh Takeuchi, Mikhail Reibarkh, Haribabu Arthanari

Erratum issuedAbstract read
In one paragraph

Article in Journal of biomolecular NMR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. The dynamic nature of the Mre11-Rad50 DNA break repair complex.Progress in biophysics and molecular biology · 2021
    Review
  3. NMR in pharmaceutical discovery and development.Journal of biomolecular NMR · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Abhinav DubeyDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Koh TakeuchiCellular and Molecular Biotechnology Research Institute & Molecular Profiling Research Center for Drug Discovery (molprof), National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, 135-0064, Japan. koh-takeuchi@aist.go.jp.
Mikhail ReibarkhAnalytical Research and Development, Merck & Co., Inc., Rahway, NJ, 07065, USA.
Haribabu ArthanariDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. hari@hms.harvard.edu.ORCID http://orcid.org/0000-0002-7281-1289

Funding

NMR Fingerprinting: Leveraging optimal control pulse design, tailored isotope labeling, and machine learning to study intractable proteinsR01GM136859 · NIGMS · DANA-FARBER CANCER INST · PI ARTHANARI, HARIBABU · 2020 to 2024
$2.4M
Japan Society for the Promotion of Science 20H04722NIGMS NIH HHS GM136859NIGMS NIH HHS R01 GM136859
6 · The paper itself

Abstract

Nuclear magnetic resonance (NMR) spectroscopy has contributed to structure-based drug development (SBDD) in a unique way compared to the other biophysical methods. The potency of a ligand binding to a protein is dictated by the binding free energy, which is an intricate interplay between entropy and enthalpy. In addition to providing the atomic resolution structural information, NMR can help to identify protein-ligand interactions that potentially contribute to the enthalpic component of the free energy. NMR can also illuminate dynamic aspects of the interaction, which correspond to the entropic term of the free energy. The ability of NMR to access both terms in the free energy equation stems from the suite of experiments developed to shed light on various aspects that contribute to both entropy and enthalpy, deepening our understanding of the biological function of macromolecules and assisting to target them in physiological conditions. Here we provide a brief account of the contribution of NMR to SBDD, highlighting hallmark examples and discussing the challenges that demand further method development. In the era of integrated biology, the unique ability of NMR to directly ascertain structural and dynamical aspects of macromolecule and monitor changes in these properties upon engaging a ligand can be combined with computational and other structural and biophysical methods to provide a more complete picture of the energetics of drug engagement with the target. Such efforts can be used to engineer better drugs.

Indexed as

Drug DesignDrug DiscoveryEntropyHydrogen BondingHydrophobic and Hydrophilic InteractionsIonsKineticsLigandsNuclear Magnetic Resonance, BiomolecularProtein BindingProtein ConformationQuantitative Structure-Activity RelationshipThermodynamicsWaterIonsLigandsWaterDrug discoveryEnthalpyEntropyFree energyNMRProtein–ligand interactionsTherapeuticsThermodynamics

Identifiers

PMID32720098
PMCPMC7686249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.